Analyst Price Targets — PHVS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 14, 2026 10:46 am | — | New Street | $60.00 | $34.04 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Pharvaris B.V. (PHVS) |
| August 13, 2026 11:04 am | — | Guggenheim | $40.00 | $36.46 | TheFly | Pharvaris price target raised to $40 from $39 at Guggenheim |
| July 15, 2026 9:32 am | Yanan Zhu | Wells Fargo | $55.00 | $34.42 | TheFly | Pharvaris initiated with an Overweight at Wells Fargo |
| June 25, 2026 10:48 am | Maxwell Skor | Morgan Stanley | $46.00 | $33.29 | TheFly | Pharvaris price target raised to $46 from $41 at Morgan Stanley |
| May 13, 2026 9:53 am | — | UBS | $74.00 | $31.25 | TheFly | Pharvaris price target lowered to $74 from $75 at Citizens |
| April 8, 2026 8:39 pm | — | Wolfe Research | $42.00 | $27.56 | TheFly | Pharvaris initiated with an Outperform at Wolfe Research |
| March 9, 2026 9:20 am | — | RBC Capital | $52.00 | $26.51 | TheFly | Pharvaris initiated with an Outperform at RBC Capital |
| December 4, 2025 12:35 pm | — | Oppenheimer | $50.00 | $29.37 | TheFly | Pharvaris price target raised to $50 from $44 at Oppenheimer |
| December 4, 2025 12:23 pm | Debjit Chattopadhyay | Guggenheim | $39.00 | $29.37 | TheFly | Pharvaris price target raised to $39 from $32 at Guggenheim |
| December 4, 2025 12:12 am | Maxwell Skor | Morgan Stanley | $41.00 | $29.37 | TheFly | Pharvaris price target raised to $41 from $37 at Morgan Stanley |
Latest News for PHVS
5AM Venture Management LLC bought a new stake in shares of Pharvaris N.V. (NASDAQ: PHVS) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 797,600 shares of the company's stock, valued at approximately $27,581,008,000. Pharvaris makes up approximately 9.6% of 5AM Venture Management
ZUG, Switzerland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the second…
ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results from the first in-depth…
Pharvaris is positioned to build a vertically integrated HAE franchise with deucrictibant in both immediate-release (IR) and extended-release (XR) forms. PHVS's NDA for deucrictibant IR was accepted by the FDA, with a PDUFA date set for April 23, 2027, following strong Phase 3 RAPIDe-3 results. The CHAPTER-3 Phase 3 data for deucrictibant XR, expected Q3 2026, is the pivotal catalyst determining PHVS's potential as…
The consensus price target hints at a 43% upside potential for Pharvaris (PHVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PHVS.
U.S. House Trading
No House trades found for PHVS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.